NuCana plc (NASDAQ:NCNA) Short Interest Down 49.1% in March

NuCana plc (NASDAQ:NCNA) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 8,800 shares, a decrease of 49.1% from the February 28th total of 17,300 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 113,200 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Trading of NuCana

Hedge funds and other institutional investors have recently modified their holdings of the stock. Two Sigma Securities LLC acquired a new position in shares of NuCana in the fourth quarter worth approximately $25,000. Citadel Advisors LLC bought a new stake in shares of NuCana in the 4th quarter valued at $30,000. Virtu Financial LLC acquired a new stake in shares of NuCana during the fourth quarter worth $48,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in shares of NuCana during the fourth quarter worth $54,000. Institutional investors own 44.00% of the company’s stock.

NuCana Stock Performance

Shares of NASDAQ NCNA traded up $0.21 during mid-day trading on Friday, reaching $1.28. The company had a trading volume of 546,725 shares, compared to its average volume of 427,030. The firm has a market cap of $3.38 million, a price-to-earnings ratio of -0.12 and a beta of 0.89. The business’s 50-day simple moving average is $0.96 and its 200 day simple moving average is $1.47. NuCana has a one year low of $0.69 and a one year high of $10.79.

NuCana (NASDAQ:NCNA) last released its earnings results on Thursday, March 20th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($2.43) by $2.11. On average, sell-side analysts anticipate that NuCana will post -13.42 EPS for the current year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.